Dr. Angela Genge (Montreal Neurological Institute-Hospital) discusses the research behind AP-101 and provides an overview of the trial and what study participation involves. The phase 2 trial of AP-101 is currently enrolling participants with Familial Amyotrophic Lateral Sclerosis and Sporadic Amyotrophic Lateral Sclerosis.
